Barclays Raises Abbott Laboratories (NYSE:ABT) Price Target to $169.00

Abbott Laboratories (NYSE:ABT) had its target price increased by Barclays from $162.00 to $169.00 in a report issued on Monday,Benzinga reports. The firm currently has an “overweight” rating on the healthcare product maker’s stock. Barclays‘s price target indicates a potential upside of 32.12% from the company’s previous close.

Other research analysts have also recently issued reports about the company. BTIG Research reiterated a “buy” rating and issued a $145.00 price target on shares of Abbott Laboratories in a research note on Thursday, November 20th. The Goldman Sachs Group upped their target price on Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a report on Wednesday, October 1st. Wells Fargo & Company lifted their price target on Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a research note on Thursday, October 16th. Benchmark initiated coverage on Abbott Laboratories in a report on Friday, October 10th. They issued a “buy” rating and a $145.00 price objective for the company. Finally, Mizuho lifted their target price on shares of Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 14th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $147.47.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $127.91 on Monday. The business has a fifty day simple moving average of $126.00 and a 200 day simple moving average of $129.51. The company has a market cap of $222.42 billion, a P/E ratio of 16.03, a P/E/G ratio of 2.09 and a beta of 0.72. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 EPS for the quarter, hitting analysts’ consensus estimates of $1.30. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. The firm had revenue of $11.37 billion during the quarter, compared to analysts’ expectations of $11.40 billion. During the same quarter in the prior year, the business earned $1.21 earnings per share. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Abbott Laboratories

Large investors have recently made changes to their positions in the company. Carr Financial Group Corp raised its stake in Abbott Laboratories by 2.0% during the 3rd quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock worth $520,000 after acquiring an additional 76 shares during the period. Tortoise Investment Management LLC increased its stake in shares of Abbott Laboratories by 10.7% in the second quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker’s stock worth $108,000 after purchasing an additional 77 shares in the last quarter. Gemmer Asset Management LLC raised its position in shares of Abbott Laboratories by 2.9% during the 3rd quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock valued at $368,000 after purchasing an additional 78 shares during the period. FF Advisors LLC boosted its holdings in Abbott Laboratories by 4.3% in the 2nd quarter. FF Advisors LLC now owns 1,904 shares of the healthcare product maker’s stock worth $259,000 after buying an additional 79 shares during the period. Finally, Charles Schwab Trust Co boosted its holdings in Abbott Laboratories by 0.6% in the 2nd quarter. Charles Schwab Trust Co now owns 14,018 shares of the healthcare product maker’s stock worth $1,907,000 after buying an additional 79 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Barclays reaffirmed a constructive view on ABT with a buy/overweight stance and raised its price target, signaling strong analyst confidence that supports further upside. Barclays Sticks to Their Buy Rating for Abbott Laboratories (ABT)
• Positive Sentiment: Barclays also increased its price target from $162 to $169 (overweight), implying meaningful upside from current levels and likely supporting buying interest. Benzinga coverage of Barclays PT raise
• Positive Sentiment: Evercore ISI nudged its target up to $144 and maintained an outperform rating, adding another independent analyst vote of confidence for valuation and growth expectations. Evercore ISI adjusts PT on Abbott Laboratories
• Positive Sentiment: Abbott unveiled Libre Assist, an AI-driven feature in the Libre app aimed at in-the-moment meal guidance for people with diabetes — a product extension that could boost user engagement and CGM stickiness. Product innovation at CES supports the narrative of recurring revenue and device ecosystem strength. Abbott’s new Libre Assist app feature
• Neutral Sentiment: Abbott scheduled its Q4 2025 earnings release and conference call for Jan. 22 (pre-market). This is a key near-term catalyst: results and FY guidance will likely drive the next leg of the stock’s move. Abbott hosts conference call for fourth-quarter earnings
• Neutral Sentiment: Studio coverage and comparisons (Zacks) highlight valuation comparisons with peers like Prestige Consumer Healthcare — useful for value-oriented investors, but not a direct stock driver. PBH vs. ABT: Which Stock Is the Better Value Option?
• Neutral Sentiment: Recent intraday/short-term coverage noting ABT’s outperformance versus the market signals momentum but is not a fundamental change. Abbott (ABT) Rises Higher Than Market: Key Facts

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.